X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with STC INDIA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs STC INDIA - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

STC INDIA 
   Change

Set up in 1956, State Trading Corporation of India Ltd. (STCIL) is a state-owned company engaged in the business of trading bulk commodities like foodgrains, edible oil, fertilizers, chemicals, pharmaceuticals, hydro-carbons, minerals. The company pl... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES STC INDIA INDOCO REMEDIES/
STC INDIA
 
P/E (TTM) x 36.6 27.8 131.4% View Chart
P/BV x 2.9 0.7 404.7% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 INDOCO REMEDIES   STC INDIA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
STC INDIA
Mar-15
INDOCO REMEDIES/
STC INDIA
5-Yr Chart
Click to enlarge
High Rs360186 193.9%   
Low Rs249140 177.9%   
Sales per share (Unadj.) Rs119.02,415.7 4.9%  
Earnings per share (Unadj.) Rs8.44.4 191.6%  
Cash flow per share (Unadj.) Rs15.27.7 197.8%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.7173.2 40.8%  
Shares outstanding (eoy) m92.1560.00 153.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.60.1 3,795.8%   
Avg P/E ratio x36.437.3 97.6%  
P/CF ratio (eoy) x20.021.2 94.6%  
Price / Book Value ratio x4.30.9 458.0%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,0839,777 287.2%   
No. of employees `0006.00.7 817.9%   
Total wages/salary Rs m2,1671,004 215.8%   
Avg. sales/employee Rs Th1,817.0196,395.8 0.9%   
Avg. wages/employee Rs Th359.01,360.6 26.4%   
Avg. net profit/employee Rs Th127.7354.9 36.0%   
INCOME DATA
Net Sales Rs m10,968144,940 7.6%  
Other income Rs m402,415 1.6%   
Total revenues Rs m11,007147,355 7.5%   
Gross profit Rs m1,565-301 -519.3%  
Depreciation Rs m633200 316.1%   
Interest Rs m621,578 3.9%   
Profit before tax Rs m909336 270.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m011 0.0%   
Extraordinary Inc (Exp) Rs m0-33 0.0%   
Tax Rs m13952 266.2%   
Profit after tax Rs m771262 294.3%  
Gross profit margin %14.3-0.2 -6,862.4%  
Effective tax rate %15.315.5 98.4%   
Net profit margin %7.00.2 3,888.9%  
BALANCE SHEET DATA
Current assets Rs m5,72524,977 22.9%   
Current liabilities Rs m5,45421,752 25.1%   
Net working cap to sales %2.52.2 110.9%  
Current ratio x1.01.1 91.4%  
Inventory Days Days620 44,919.6%  
Debtors Days Days7261 117.5%  
Net fixed assets Rs m5,3079,599 55.3%   
Share capital Rs m184600 30.7%   
"Free" reserves Rs m6,3319,789 64.7%   
Net worth Rs m6,51610,389 62.7%   
Long term debt Rs m1,3231,763 75.1%   
Total assets Rs m11,97046,589 25.7%  
Interest coverage x15.61.2 1,289.8%   
Debt to equity ratio x0.20.2 119.7%  
Sales to assets ratio x0.93.1 29.5%   
Return on assets %7.03.9 176.2%  
Return on equity %11.82.5 469.2%  
Return on capital %12.415.6 79.6%  
Exports to sales %00.9 0.0%   
Imports to sales %077.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA111,860 0.0%   
Fx inflow Rs m4,5071,264 356.6%   
Fx outflow Rs m1,141111,912 1.0%   
Net fx Rs m3,366-110,648 -3.0%   
CASH FLOW
From Operations Rs m886244 363.7%  
From Investments Rs m-1,706166 -1,029.3%  
From Financial Activity Rs m1,316-926 -142.2%  
Net Cashflow Rs m497-516 -96.2%  

Share Holding

Indian Promoters % 59.2 90.0 65.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 2.0 625.0%  
FIIs % 6.0 0.2 3,000.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 7.9 283.5%  
Shareholders   12,805 27,829 46.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   BAJAJ FINANCE  COX & KINGS  COMMEX TECHNOLOGY  THOMAS COOK INDIA  MIC ELECTRONICS  



Today's Market

Sensex Opens Lower; Realty & Auto Stocks Top Losers(09:30 am)

Asian shares eased in holiday-thinned trading on Monday and the safe haven yen gained as China canceled upcoming tariff talks with the United States.

Related Views on News

STC INDIA Announces Quarterly Results (4QFY18); Net Profit Down 124.5% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, STC INDIA has posted a net profit of Rs 20 m (down 124.5% YoY). Sales on the other hand came in at Rs 21 bn (down 28.0% YoY). Read on for a complete analysis of STC INDIA's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY18); Net Profit Up 14.3% (Quarterly Result Update)

Jun 19, 2018 | Updated on Jun 19, 2018

For the quarter ended March 2018, INDOCO REMEDIES has posted a net profit of Rs 205 m (up 14.3% YoY). Sales on the other hand came in at Rs 3 bn (down 2.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 24, 2018 12:37 PM

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES - NESCO LIMITED COMPARISON

COMPARE INDOCO REMEDIES WITH

MARKET STATS